Literature DB >> 6607104

Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus.

J A Byrne, M Soloski, J A Holowczak.   

Abstract

Cell-mediated immune responses in DBA/2 mice bearing melanoma tumors (TB-mice) were measured and compared to similar responses in mice without tumors (C-mice). Splenic lymphocytes from TB-mice had a reduced capacity to respond to both B and T-cell mitogens, but TB-mice responded to infection with vaccinia virus by developing a virus-specific cytotoxic T-cell response equal to that measured with splenic effectors prepared from virus-infected C-mice. NK-cell activity, as measured by the in vitro lysis of YAC-1 targets by splenic effectors, was significantly depressed in TB-mice but, after infection of the animals with vaccinia virus, was restored to levels equal to that measured with splenic effectors prepared from C-mice. Doses of vaccinia virus, strain WR which elicited vaccinia-virus-specific cytotoxic T cells or stimulated NK-cell activity, failed to elicit or stimulate cytotoxic effectors specific for S91-melanoma tumor cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6607104     DOI: 10.1007/bf00199236

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

1.  The purification fo four strains of poxvirus.

Authors:  W K JOKLIK
Journal:  Virology       Date:  1962-09       Impact factor: 3.616

Review 2.  Viral xenogenization of intact tumor cells.

Authors:  H Kobayashi
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

Review 3.  An analysis of the murine NK cell as to structure, function and biological relevance.

Authors:  R Kiessling; H Wigzell
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

4.  Use of vaccinia virus in the treatment of metastatic malignant melanoma.

Authors:  I Hunter-Craig; K A Newton; G Westbury; B W Lacey
Journal:  Br Med J       Date:  1970-05-30

5.  Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice. II. "Specificities" of the natural killer cells.

Authors:  R M Welsh; R M Zinkernagel; L A Hallenbeck
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

6.  A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses.

Authors:  W C Russell; C Newman; D H Williamson
Journal:  Nature       Date:  1975-02-06       Impact factor: 49.962

7.  Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice.

Authors:  H Kirchner; A V Muchmore; T M Chused; H T Holden; R B Herberman
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

8.  Cytotoxicity of lymphocytes from healthy subjects and from melanoma patients against cultured melanoma cells.

Authors:  J Pavie-Fischer; F M Kourilsky; F Picard; P Banzet; A Puissant
Journal:  Clin Exp Immunol       Date:  1975-09       Impact factor: 4.330

9.  Splenic regulation of the clinical appearance of small tumors.

Authors:  J J Nordlund; R K Gershon
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

10.  Human natural killer cell activity is augmented by interferon via recruitment of 'pre-NK' cells.

Authors:  E Saksela; T Timonen; K Cantell
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

View more
  3 in total

1.  Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia.

Authors:  J S Bryson; D C Cox
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

Authors:  R J Natuk; J A Byrne; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  The immune response to vaccinia virus infection in mice: analysis of the role of antibody.

Authors:  F J Novembre; K Raska; J A Holowczak
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.